NewEdge Advisors LLC Acquires 2,933 Shares of Charles River Laboratories International, Inc. $CRL

NewEdge Advisors LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,119.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,195 shares of the medical research company’s stock after purchasing an additional 2,933 shares during the quarter. NewEdge Advisors LLC’s holdings in Charles River Laboratories International were worth $551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Vanguard Group Inc. lifted its stake in Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after buying an additional 47,432 shares during the period. Avidity Partners Management LP acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $1,670,000. Maverick Capital Ltd. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $1,411,000. WINTON GROUP Ltd bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $9,209,000. Finally, M&T Bank Corp increased its stake in shares of Charles River Laboratories International by 1,424.9% in the 4th quarter. M&T Bank Corp now owns 27,997 shares of the medical research company’s stock valued at $5,585,000 after acquiring an additional 26,161 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the topic of several research analyst reports. Barclays reissued an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Mizuho set a $264.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Finally, Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $295.23 on Friday. The company has a fifty day simple moving average of $234.99 and a 200 day simple moving average of $193.86. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $299.32. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a market cap of $14.09 billion, a P/E ratio of -60.87, a PEG ratio of 3.02 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the previous year, the business posted $3.12 EPS. Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Victoria L. Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This trade represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 132,429 shares of company stock valued at $32,538,088 over the last quarter. 1.30% of the stock is currently owned by company insiders.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration
• Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers
• Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity
• Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook
• Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale
• Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.